Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QB3@953, a San Francisco incubator created by QB3, a University of California (UC) research institute and biotech accelerator, announced an agreement with pharmaceutical company GSK to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
Subscribe to our email newsletter
The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement augments DPAc’s direct outreach to universities and institutions as well as its Discovery Fast Track program.
Under the terms of the agreement, QB3@953 will work closely with GSK to identify innovators who are exploring targets with therapeutic potential and a defined clinical hypothesis. QB3@953 will also help facilitate collaborations between these researchers and GSK.
The new agreement combines the resources and capabilities of GSK with the equipment, lab space and services available at QB3@953 to give the scientists what they need to advance their research toward new medicines.
"This is about finding innovators with great biology and connecting them with GSK’s tremendous drug discovery and development capabilities," said Douglas Crawford, PhD, associate director of QB3 and founder of QB3@953.
"The incubator model is an exciting path for researchers to advance their early target concepts. We expect that our agreement with QB3@953 will identify researchers keen on collaborations that integrate their biological knowledge with the drug development expertise of GSK," said Carolyn Buser-Doepner, Head of DPAc.